Nov 27 (Reuters) - The U.S. Food and Drug Administration

is weighing the need for a regulatory action on bluebird bio's

gene therapy for a rare neurological disorder, it said

on Wednesday, as the agency probes additional reports of blood

cancers from its use.

Skysona was approved by the FDA in 2022 for the treatment of

cerebral adrenoleukodystrophy.

The therapy's prescribing information included a warning for

blood cancers, including leukemia and myelodysplastic syndromes,

which are a group of cancers that occur when the bone marrow

produces immature blood cells instead of healthy ones.

The FDA said considering the risk of such cancers, patients

should consider alternative therapies.